Hookipa Pharma price target raised to $6 from $5 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Hookipa Pharma to $6 from $5 and keeps a Buy rating on the shares. Hookipa presented additional positive data from its Phase 2 study evaluating HB-200 plus pembrolizumab as first-line treatment of recurrent/metastatic human papillomavirus 16 positive head and neck squamous cell carcinoma, the analyst tells investors in a research note. The firm believes HB-200 plus pembrolizumab have a high likelihood to outperform placebo plus pembrolizumab in its planned Phase 2/3 pivotal study. It increased its probability of launch of HB-200 to 70% from 50%.